Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Chemistry World April 27, 2015 Ned Stafford	European parliament refuses to back diversion of research cash Key European parliament committees have overwhelmingly rejected a proposal to divert euro 2.7 billion of research funding to help finance a new EU-wide economic stimulus package.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Chemistry World May 2006 Bea Perks	Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.
Pharmaceutical Executive May 1, 2007 Kevin A. Schulman	Kid Tested, Government Approved? Critics claim pharma is too richly rewarded for studying drugs in children. Now, several legislative proposals are on the table that just might change that.
Pharmaceutical Executive February 1, 2009 Sarah Houlton	Reforms Offer Good News for Trade European Commission proposal loosens restrictions on drug packaging and information dissemination.
Chemistry World December 4, 2014 Ned Stafford	Plan to divert EU research cash into investment fund gets chilly response from scientists The proposal would see the money moved from Horizon 2020 into a new investment fund to bolster Europe's economy and create jobs.
Pharmaceutical Executive February 1, 2006 Sarah Houlton	Global Report: Moving Towards Generic Biologics The European Medicines Agency hopes to complete its guidelines for the approval of biosimilar drugs early this year, paving the way for the approval of biogenerics - and a potential goldmine for the generics companies.
Pharmaceutical Executive June 1, 2011	A Lack of Information Why has the EU still not managed to update its rules on information about medicines?
Chemistry World October 29, 2007 Arthur Rogers	Deal to Allow Poor Nations Better Access to Cheap Drugs MEPs belatedly approved EU ratification of a 2005 World Trade Organization protocol on compulsory licensing -- potentially paving the way for developing countries to order generic drugs from manufacturers abroad without infringing patent rights.
Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
Chemistry World July 11, 2012	Europe-Wide Single Patent Stalls Again A single European patent is on the wish list of small innovative businesses.
Chemistry World January 6, 2014 Sarah Houlton	Weathering the storm Pharma is in the middle of a strategic crisis, if a report published at the start of 2013 by Roland Berger Strategy Consultants is to be believed.
Chemistry World May 15, 2015 Rebecca Trager	Trade agreement could limit access to medicines A leaked draft of a trade agreement under negotiation among 12 Pacific rim countries, including the US and Japan, contains language that could delay the entrance of generic competition for much-needed medicines.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Pharmaceutical Executive October 1, 2011 Jill Wechsler	"Representing" Healthcare to the Fullest Since coming to Congress about 35 years ago, Henry Waxman, Congressional Representative from Los Angeles, California, has been pivotal in shaping legislation on health and drug regulatory issues.
Chemistry World September 30, 2014	Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Pharmaceutical Executive July 1, 2014	Europe Gears Up to Attack Counterfeit Medicines -- But Only Some of Them Cross-sector partnership seeks support for a pan-European system to keep fake drugs out, but obstacles are many.
Pharmaceutical Executive August 1, 2013	Pharma Bids for European Funding in New Research Program The euro 70 billion budget is still subject to final agreement on the European Union's overall spending plans for 2014-2020.
Chemistry World April 24, 2014 Emma Stoye	European parliament backs new rules on legal highs New regulations that will make it easier to ban legal highs have been backed by the European parliament.
Chemistry World January 20, 2010 Phil Taylor	Screw tightens on pay-for-delay drug deals Scrutiny of the tactics used by pharmaceutical companies to delay the entry of generics onto the market is rising on both sides of the Atlantic amid claims that the practice is costing consumers billions every year.
InternetNews July 6, 2005 Jim Wagner	European Parliament Rejects Software Patents After three years of debate, legislation to provide unified software patent protections across the EU is halted.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
Chemistry World June 1, 2015 Ned Stafford	Scientists hail partial victory on efforts to block cuts to European research programme All-night negotiations between European politicians led to the protection of key areas of the EU's research program.
Chemistry World August 2, 2007 Victoria Gill	Europe Poised for a Surge in Generic Drugs The European Medicines Agency's Committee for Medicinal Products for Human use has recommended the approval of a schizophrenia treatment which is the first generic drug to be assessed under Europe's centralized procedure.
Chemistry World January 15, 2014 Dinsa Sachan	Radical drug rule changes hit buffers in India A parliamentary panel in India has slammed a proposed bill seeking to radically alter the way drugs are regulated in India. The panel's report has essentially put reform of medicines in the country on ice, according to observers.
Chemistry World October 8, 2014 Phillip Broadwith	EMA finalizes trial transparency rules The European Medicines Agency has finalized its policy for sharing data from clinical trials.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive January 1, 2014 Jill Wechsler	Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing
Chemistry World November 3, 2015 Ned Stafford	GM food and feed law falters in EU parliament Both GMO supporters and opponents applauded parliament's rejection of the proposed law.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
Pharmaceutical Executive October 1, 2010	Euro Soul-Searching on Competition A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers.
Pharmaceutical Executive January 1, 2007 Jill Wechsler	Washington Report: A Full Plate It's going to be a busy year in Washington for the pharmaceutical industry. Drug safety, unapproved uses, e-data requirements, and a shift to personalized medicine are just a few of the hot issues on tap for 2007.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
Chemistry World August 17, 2015 Anthony King	Greek crisis puts pressure on pharmaceuticals Supplies of critical drugs to Greek pharmacies have become sparse and erratic as the economic crisis squeezes public spending
Pharmaceutical Executive July 30, 2007 Jill Wechsler	Washington Report: Exclusivity vs. Patents To encourage innovation while supporting access to less costly therapies, Congress proposes an extensive data-exclusivity period that would delay Food and Drug Administration approval of a follow-on biologic application for 12 years.
Bio-IT World November 2005 Patrick R. Scanlon	Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Chemistry World January 7, 2014 Angeli Mehta	Flu drug stockpile may be worthless The case for spending hundreds of millions of pounds stockpiling antivirals for use in a flu pandemic is based on 'judgement rather than on evidence of their effectiveness', according to a parliamentary committee.
Pharmaceutical Executive September 1, 2014	Peril, Not Progress on Transatlantic Trade Deal Pharma hopes for a deal are fading as the once-hot TTIP talks seem to be on the fizzle in Europe.
Pharmaceutical Executive March 1, 2012 Jill Wechsler	When Talk is Not So Cheap FDA and industry are pushing user fees, while they struggle with curbs on communications.
Pharmaceutical Executive March 1, 2006 Sarah Houlton	Global Report: Chemicals Legislation in Europe Chemicals legislation in Europe may affect pharma's relationship with suppliers.
Pharmaceutical Executive February 1, 2014	Will Europe's Regulatory Watchdog Come Of Age In 2014? The author looks at the growing pains of the European Medicine Agency as it faces key policy challenges of 2014.